AMT presents long-term efficacy study of Glybera in treatment of lipoprotein lipase deficiency

Links shared publicly online about this topic.

279
total visits

AMT presents long-term efficacy study of Glybera in treatment of lipoprotein lipase deficiency

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today results from a long-term efficacy study of Glybera (alipogene tiparvovec) that showed improved chylomicron metabolism could be used as a biomarker for increased lipoprotein lipase (LPL) activity in those patients missing the gene that produces this protein.

View full resource at news-medical.net

Tags: Parkinson's Disease, Disease and Condition, Protein, Genes, disease